Nathalie Cartier-Lacave to Amyloid beta-Peptides
This is a "connection" page, showing publications Nathalie Cartier-Lacave has written about Amyloid beta-Peptides.
Connection Strength
0.210
-
Audrain M, Fol R, Dutar P, Potier B, Billard JM, Flament J, Alves S, Burlot MA, Dufayet-Chaffaud G, Bemelmans AP, Valette J, Hantraye P, D?glon N, Cartier N, Braudeau J. Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. Mol Neurodegener. 2016 Jan 12; 11:5.
Score: 0.107
-
Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bi?che I, Marquer C, Chali F, Ayciriex S, Auzeil N, Alves S, Langui D, Potier MC, Laprevote O, Vidaud M, Duyckaerts C, Miles R, Aubourg P, Cartier N. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer's disease. Brain. 2015 Aug; 138(Pt 8):2383-98.
Score: 0.103